OCX

Insight Molecular Diagnostics Inc. (OCX) | Rumor.io

Insight Molecular Diagnostics

OCX

Attention (50-day avg)0%

Attention rank (50-day avg)#4,854

Bullish sentiment (50-day avg)—

Price to earnings ratio-0.68

Market capitalization55.5M

Earnings per share-4.66

Dividend yield (TTM)—

Revenue (annual)1.9M

Net income (annual)-60.7M

Social

What share of all stock conversation is about OCX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Feb 10

OncoCyte Corporation's ($OCX) token migration is now complete, and users can claim their tokens by connecting their wallet.
The company's prediction market platform, OutcomeX, is gaining popularity and expected to continue growing, providing a one-stop terminal for users to access various prediction markets.
The company's token, $OCX, is considered a strong investment opportunity, with some investors holding it as a top pick in their portfolio.

Generated by AI

Sentiment

Of the messages about OCX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% 0
Bearish	—	—	—	0% 0

Dec 15

OncoCyte Corporation ($OCX) has seen a 75% increase in premarket and may experience a squeeze.
The company has entered a licensing agreement with Burning Rock (BNR) to test for early stage lung-cancer patients in China, resulting in a 58.5% increase.
$OCX is experiencing high volume and may see further gains, with some analysts suggesting a target resistance of $4.60-5.60.

Generated by AI

Topics

Of the messages about OCX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

May 11

Oncocyte Corporation reported its first quarter 2023 financial results, with the details of the filing available on the SEC website.
The company's financial performance for the quarter was not specified in the announcements.
The filings were made on May 11, 2023, with the relevant documents available for public review.

Generated by AI

Community

Of the messages about OCX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	40.91%
Newcomers	—	100%	100%	59.09%

Regulars· Aug 18

Multiple OncoCyte Corporation insiders have purchased shares, with Griffith Melinda, Director, buying 10,000 shares and increasing her stake by 50%, and John Peter Gutfreund, Director, buying 25,000 shares and increasing his stake by 250%.
OncoCyte Corporation's share price has moved below its 50-day Moving Average, and the company's insiders are actively buying shares, with Alfred D Kingsley, Director, buying 10,000 shares and Ronald Asbury Andrews, President & CEO, buying 40,000 shares.
OncoCyte Corporation insiders have made significant purchases of shares, with Jennifer L. Carter, Director, buying 10,500 shares and Douglas T. Ross, Chief Scientific Officer, being granted 150,000 shares, increasing his holding by 738%.

Newcomers· May 11

OncoCyte Corporation's stock price is up 4.95% after hours, likely in response to its first quarter 2023 financial results.
The company has reported its first quarter 2023 financial results, which is a significant development for the asset.
The asset's performance in the first quarter 2023 is a key focus for newcomers, with many posts discussing the company's financial results.

Generated by AI

Also Discussed

Investors talking about OCX also mention

#	Name	Attention
1	Lineage Cell Therapeutics Inc.LCTX	0%-0.01
2	Perspective Therapeutics Inc.CATX	0%+0
3	Avenue Therapeutics Inc.ATXI	0%new
4	Optical Cable CorporationOCC	0%new
5	American Assets Trust IncAAT	0%0
6	Nemaura Medical Inc.NMRD	0%new
7	Homology Medicines IncFIXX	0%0
8	Daxor CorporationDXR	0%0
9	Bio-Path Holdings Inc.BPTH	0%0
10	PEDEVCO Corp.PED	0%new

Insight Molecular Diagnostics Inc.

Healthcare
Diagnostics & Research

Insight Molecular Diagnostics Inc. is a molecular diagnostics company focused on precision testing for transplantation and oncology. The company develops and commercializes laboratory-developed, kitted research-use, and clinical diagnostic tests that help clinicians assess organ rejection, monitor therapeutic response, and characterize tumor biology. Its current portfolio includes GraftAssure, a blood-based platform for transplanted organ health monitoring, along with oncology assays such as DetermaIO and DetermaCNI. Insight Molecular Diagnostics also supports researchers, pharmaceutical customers, and healthcare systems with molecular diagnostic services and precision medicine solutions. Headquartered in Nashville, Tennessee, the company operates a clinical laboratory that serves U.S. medical and research markets.

Website

Location

2 International Plaza Dr.

Nashville, TN, 37217

United States

Social

What share of all stock conversation is about OCX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Feb 10

OncoCyte Corporation's ($OCX) token migration is now complete, and users can claim their tokens by connecting their wallet.
The company's prediction market platform, OutcomeX, is gaining popularity and expected to continue growing, providing a one-stop terminal for users to access various prediction markets.
The company's token, $OCX, is considered a strong investment opportunity, with some investors holding it as a top pick in their portfolio.

Generated by AI

Sentiment

Of the messages about OCX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% 0
Bearish	—	—	—	0% 0

Dec 15

OncoCyte Corporation ($OCX) has seen a 75% increase in premarket and may experience a squeeze.
The company has entered a licensing agreement with Burning Rock (BNR) to test for early stage lung-cancer patients in China, resulting in a 58.5% increase.
$OCX is experiencing high volume and may see further gains, with some analysts suggesting a target resistance of $4.60-5.60.

Generated by AI

Topics

Of the messages about OCX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

May 11

Oncocyte Corporation reported its first quarter 2023 financial results, with the details of the filing available on the SEC website.
The company's financial performance for the quarter was not specified in the announcements.
The filings were made on May 11, 2023, with the relevant documents available for public review.

Generated by AI

Community

Of the messages about OCX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	40.91%
Newcomers	—	100%	100%	59.09%

Regulars· Aug 18

Multiple OncoCyte Corporation insiders have purchased shares, with Griffith Melinda, Director, buying 10,000 shares and increasing her stake by 50%, and John Peter Gutfreund, Director, buying 25,000 shares and increasing his stake by 250%.
OncoCyte Corporation's share price has moved below its 50-day Moving Average, and the company's insiders are actively buying shares, with Alfred D Kingsley, Director, buying 10,000 shares and Ronald Asbury Andrews, President & CEO, buying 40,000 shares.
OncoCyte Corporation insiders have made significant purchases of shares, with Jennifer L. Carter, Director, buying 10,500 shares and Douglas T. Ross, Chief Scientific Officer, being granted 150,000 shares, increasing his holding by 738%.

Newcomers· May 11

OncoCyte Corporation's stock price is up 4.95% after hours, likely in response to its first quarter 2023 financial results.
The company has reported its first quarter 2023 financial results, which is a significant development for the asset.
The asset's performance in the first quarter 2023 is a key focus for newcomers, with many posts discussing the company's financial results.

Generated by AI

Insight Molecular Diagnostics

Social

Feb 10

Sentiment

Dec 15

Topics

May 11

Community

Regulars· Aug 18

Newcomers· May 11

News

Oncocyte Q2 Earnings Call Highlights

Also Discussed

Insight Molecular Diagnostics Inc.

Company Information

Location

News

Oncocyte Q2 Earnings Call Highlights

Also Discussed

Social

Feb 10

Sentiment

Dec 15

Topics

May 11

Community

Regulars· Aug 18

Newcomers· May 11